Given the notion that the modulation of NFκB transcriptional activity is an effective therapeutic strategy for cancer, we hypothesized that RH, being a potent inhibitor of NFκB, could reveal therapeutic potentialities in oncology. The gene discussed is NFKB1; the disease is cancer.